Abstract
Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Current Gene Therapy
Title: TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy
Volume: 4 Issue: 1
Author(s): W. Liu, D. R. Wang and Y. L. Cao
Affiliation:
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Abstract: Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Export Options
About this article
Cite this article as:
Liu W., Wang R. D. and Cao L. Y., TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy, Current Gene Therapy 2004; 4 (1) . https://dx.doi.org/10.2174/1566523044578004
DOI https://dx.doi.org/10.2174/1566523044578004 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Opportunities Offered by Chitosan-Based Nanotechnology in Mucosal/ Skin Drug Delivery
Current Topics in Medicinal Chemistry Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science The Physiology, Pharmacology and Future of P2X7 as An Analgesic Drug Target: Hype or Promise?
Current Pharmaceutical Biotechnology Effects of Melatonin on Peripheral Nerve Regeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets